Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more effective than getting weight loss surgery.

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... said that “this study was helpful to show that some muscle can occur with significant ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after revenue more than doubled, and it raised full-year guidance. Revenue hit $ ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

GLP-1 drugs have helped ... on proper medication use, resistance training, and adequate protein intake. Body composition was measured at the start of the study, at three months, and again at ...